JP2024539922A - ピリジル含有化合物 - Google Patents

ピリジル含有化合物 Download PDF

Info

Publication number
JP2024539922A
JP2024539922A JP2024523981A JP2024523981A JP2024539922A JP 2024539922 A JP2024539922 A JP 2024539922A JP 2024523981 A JP2024523981 A JP 2024523981A JP 2024523981 A JP2024523981 A JP 2024523981A JP 2024539922 A JP2024539922 A JP 2024539922A
Authority
JP
Japan
Prior art keywords
compound
mixture
alkyl
alternatively
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539922A5 (cg-RX-API-DMAC7.html
Inventor
飛 劉
宏 江 徐
岩 彭
偉 施
佳 偉 周
佳 佳 顧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2024539922A publication Critical patent/JP2024539922A/ja
Publication of JP2024539922A5 publication Critical patent/JP2024539922A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024523981A 2021-10-29 2022-10-28 ピリジル含有化合物 Pending JP2024539922A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202111269381.X 2021-10-29
CN202111269381 2021-10-29
CN202210233624 2022-03-10
CN202210233624.2 2022-03-10
CN202210849103.X 2022-07-19
CN202210849103 2022-07-19
CN202211274771 2022-10-18
CN202211274771.0 2022-10-18
PCT/CN2022/128251 WO2023072248A1 (zh) 2021-10-29 2022-10-28 含吡啶基的化合物

Publications (2)

Publication Number Publication Date
JP2024539922A true JP2024539922A (ja) 2024-10-31
JP2024539922A5 JP2024539922A5 (cg-RX-API-DMAC7.html) 2025-10-28

Family

ID=86159245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523981A Pending JP2024539922A (ja) 2021-10-29 2022-10-28 ピリジル含有化合物

Country Status (11)

Country Link
US (1) US20250002472A1 (cg-RX-API-DMAC7.html)
EP (1) EP4424676A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539922A (cg-RX-API-DMAC7.html)
KR (1) KR20240090588A (cg-RX-API-DMAC7.html)
CN (1) CN118055924A (cg-RX-API-DMAC7.html)
AU (1) AU2022376773A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235436A1 (cg-RX-API-DMAC7.html)
IL (1) IL312179A (cg-RX-API-DMAC7.html)
MX (1) MX2024004871A (cg-RX-API-DMAC7.html)
TW (1) TW202321220A (cg-RX-API-DMAC7.html)
WO (1) WO2023072248A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222900A1 (zh) * 2023-04-28 2024-10-31 正大天晴药业集团股份有限公司 含三唑基的化合物
WO2026082075A1 (zh) * 2024-10-15 2026-04-23 杭州百诚医药科技股份有限公司 丙烯酰胺类化合物及其医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522266A (ja) * 2013-06-21 2016-07-28 カリオファーム セラピューティクス,インコーポレイテッド 核内輸送調節因子およびその使用
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526295B2 (en) * 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
CN110592141B (zh) * 2018-06-13 2023-07-07 中国科学院上海有机化学研究所 用于调控基因编辑效率的化合物及其应用
WO2021252900A1 (en) * 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
CN112538069A (zh) * 2020-11-05 2021-03-23 苏州艾和医药科技有限公司 一种氮唑类衍生物或其药物可接受盐及其制备方法和用途
CN113045550A (zh) * 2021-03-12 2021-06-29 深圳济康医药科技有限公司 一种三氮唑类衍生物及其制备方法和应用
CN113248474A (zh) * 2021-05-24 2021-08-13 王能能 五元氮唑杂环衍生物及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522266A (ja) * 2013-06-21 2016-07-28 カリオファーム セラピューティクス,インコーポレイテッド 核内輸送調節因子およびその使用
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
野崎正勝 等, 創薬化学, vol. 第1版, JPN6012059719, 1995, pages 98 - 99, ISSN: 0005918291 *

Also Published As

Publication number Publication date
CN118055924A (zh) 2024-05-17
EP4424676A4 (en) 2025-11-12
WO2023072248A1 (zh) 2023-05-04
EP4424676A1 (en) 2024-09-04
CA3235436A1 (en) 2023-05-04
AU2022376773A1 (en) 2024-05-23
IL312179A (en) 2024-06-01
TW202321220A (zh) 2023-06-01
US20250002472A1 (en) 2025-01-02
MX2024004871A (es) 2024-05-06
KR20240090588A (ko) 2024-06-21

Similar Documents

Publication Publication Date Title
JP7752638B6 (ja) リン含有sos1阻害剤
EP3848367A1 (en) Tricyclic compounds acting on crbn proteins
JP7558977B2 (ja) メチル基及びトリフルオロメチル基を含む二置換スルファミド系選択的bcl-2阻害剤
JP7808098B2 (ja) Aktキナーゼ阻害剤としての化合物
WO2023208143A1 (zh) 一种吡唑取代环戊酯衍生物及其用途
CN112867717A (zh) 用作激酶抑制剂的化合物及其应用
CN116547276A (zh) 含酰胺基和杂环烷基的tyk2抑制剂化合物
JP7818610B2 (ja) 連環を含むtyk2阻害剤化合物
JP2026507476A (ja) トリフルオロメタンスルホニル基を含む化合物
KR20240167844A (ko) 질소 함유 헤테로시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용
KR20240090588A (ko) 피리딜 함유 화합물
AU2024289347A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
CN121039118A (zh) 含三唑基的化合物
JP2025503055A (ja) ヒドラジン基含有化合物
TW202440110A (zh) 含有二氫酞嗪及烯基的化合物以及其用途
EP4617272A1 (en) Fused bicyclic compound
CN115925689A (zh) 含环丙基的核输出蛋白抑制剂
HK40111379A (en) Pyridyl-containing compound
KR20230158659A (ko) Ctla-4 소분자 분해제 및 그 응용
CN116813646A (zh) 取代桥环类抑制剂及其制备方法和应用
CN116730984A (zh) 含吡啶基的化合物
EA051207B1 (ru) Пиридилсодержащее соединение
CN110776511A (zh) 含喹啉环的btk抑制剂
CN116135851B (zh) 一种芳香胺化合物及其应用
CN117050055A (zh) 含有酰胺吡啶环的化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260728